Category: Hologic Inc.
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast tomosynthesis mammography system, saying the new software will help reduce exposure to radiation.
Hologic (NSDQ:HOLX) won pre-market approval from the FDA for mammography software it says will help reduce patients' exposure to radiation.
The Bedford, Mass.-based women's health company said its C-View 2D imaging software is meant to replace conventional 2D exposure, a component of Hologic's 3D 3D breast tomosynthesis mammography system.
A list of some of the tax tabs for medical device companies for the medical device excise tax during Q1
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013
Shares of Hologic fall under pressure after the women's health company misses its own sales forecast and lowers its sales and earnings outlook for the rest of the year.
Hologic (NSDQ:HOLX) shares shed more than 4% today after the women's health company said yesterday that it missed its own 2nd-quarter sales forecast and lowered its top- and bottom-line outlooks for the rest of fiscal 2013.
Private equity players Bain Capital, Carlyle Group and KKR & Co. are in the hunt for medical device company Carestream, said to be on the auction block for up to $3.5 billion.
At least 5 major private equity players are vying for medical device company Carestream Health, including Bain Capital, Carlyle Group and KKR & Co., according to Reuters.
Onex Corp. is hoping to unload Carestream, formed in the 2007 spinout of Eastman Kodak Co.'s healthcare business, for up to $3.5 billion, the news service reported.
A federal judge stays a patent infringement lawsuit filed by C.R. Bard subsidiary SenoRx over Hologic's Mammosite device for treating breast cancer.
A federal judge in Delaware put a patent infringement spat between C.R. Bard subsidiary SenoRx and Hologic (NSDQ:HOLX) on hold for 90 days last week.
